share_log

Sanofi | 6-K: Dupixent® FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) and François-Xavier Roger Appointed Chief Financial Officer, Member of Sanofi Executive Committee

赛诺菲安万特 | 6-K:Dupixent ®获FDA批准作为第一个也是唯一一个治疗1岁及以上儿童嗜酸粒细胞性食管炎(EoE)的药物以及François-Xavier Roger被任命为赛诺菲安万特首席财务官兼执行委员会成员

美股SEC公告 ·  02/02 13:26
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息